Esperion Therapeutics ESPR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $418.24M+61.1% | $403.14M+21.3% | $303.8M+2.8% | $268.13M-3.5% | $259.57M+13.0% | ||
| $44.28M-2.4% | $47.85M+3.5% | $44.9M-15.3% | $41.17M-28.4% | $45.39M-33.4% | ||
| $165.91M+1.1% | $165.79M+1.7% | $161.28M-6.0% | $159.41M-3.3% | $164.08M+6.1% | ||
| $342.46M+14.3% | $342.86M+23.4% | $333.18M+19.4% | $303.57M+11.3% | $299.54M+13.3% | ||
| —— | $129.22M+88.4% | $114.07M+83.2% | $98.91M+76.8% | $83.76M+68.9% | ||
| $75.79M+313% | $60.27M+2.5% | -$24.96M-252% | -$31.03M-727% | -$35.54M-2.5% | ||
| 18.1%+31.8pp | 15%-2.7pp | -8.2%-13.8pp | -11.6%-13.4pp | -13.7%+1.4pp | ||
| $84.97M+31.4% | $84.6M+42.8% | $78.39M+35.4% | $71.42M+23.6% | $64.66M+10.3% | ||
| $3.6M-43.0% | $3.49M-56.5% | $3.62M-54.1% | $4.53M-40.3% | $6.32M-7.0% | ||
| —— | -$20.84M+59.7% | -$28.57M+68.6% | -$36.29M+72.2% | -$44.02M+74.1% | ||
| —— | $1.84M— | $1.38M— | $920.5K— | $460.25K— | ||
| —— | —— | -$105.83M-22.0% | -$104.02M-5.6% | -$153.22M-77.1% | ||
| —— | —— | -$0.54+15.6% | -$0.53+38.4% | -$0.80+19.2% | ||
| $75.89M+314% | $60.38M+2.5% | -$24.85M-251% | -$30.92M-720% | -$35.45M-2.5% | ||
| 18.1%+31.8pp | 15%-2.7pp | -8.2%-13.8pp | -11.5%-13.3pp | -13.7%+1.4pp | ||
| $75.79M+313% | $60.27M+2.5% | -$24.96M-252% | -$31.03M-727% | -$35.54M-2.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Esperion Therapeutics's revenue?
- Esperion Therapeutics (ESPR) generated $418.2M in revenue over the trailing twelve months, up 61.1% year over year.
- Is Esperion Therapeutics profitable?
- Esperion Therapeutics is not currently profitable: it reported a net loss of $109.7M over the trailing twelve months, a -34.8% net margin.
- What is Esperion Therapeutics's earnings per share?
- Esperion Therapeutics's diluted EPS over the trailing twelve months is $-0.53.
- Where does Esperion Therapeutics's income statement data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
